JPWO2022063803A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022063803A5 JPWO2022063803A5 JP2023518392A JP2023518392A JPWO2022063803A5 JP WO2022063803 A5 JPWO2022063803 A5 JP WO2022063803A5 JP 2023518392 A JP2023518392 A JP 2023518392A JP 2023518392 A JP2023518392 A JP 2023518392A JP WO2022063803 A5 JPWO2022063803 A5 JP WO2022063803A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell
- bispecific antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 59
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 16
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000004127 Cytokines Human genes 0.000 claims 13
- 108090000695 Cytokines Proteins 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 230000002411 adverse Effects 0.000 claims 9
- 230000005764 inhibitory process Effects 0.000 claims 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 5
- 108090001005 Interleukin-6 Proteins 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 5
- 102100037850 Interferon gamma Human genes 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000007896 negative regulation of T cell activation Effects 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 206010052015 cytokine release syndrome Diseases 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000025020 negative regulation of T cell proliferation Effects 0.000 claims 2
- 230000019079 negative regulation of cytokine secretion Effects 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- -1 IFN- γ Proteins 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 claims 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 230000009437 off-target effect Effects 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 102000009076 src-Family Kinases Human genes 0.000 claims 1
- 108010087686 src-Family Kinases Proteins 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20198050.5 | 2020-09-24 | ||
| EP20198050 | 2020-09-24 | ||
| EP20201583.0 | 2020-10-13 | ||
| EP20201583 | 2020-10-13 | ||
| EP21172627 | 2021-05-07 | ||
| EP21172627.8 | 2021-05-07 | ||
| PCT/EP2021/075995 WO2022063803A1 (en) | 2020-09-24 | 2021-09-22 | Prevention or mitigation of t-cell bispecific antibody-related adverse effects |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542212A JP2023542212A (ja) | 2023-10-05 |
| JPWO2022063803A5 true JPWO2022063803A5 (https=) | 2024-09-30 |
| JP2023542212A5 JP2023542212A5 (https=) | 2024-09-30 |
Family
ID=78000677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518392A Pending JP2023542212A (ja) | 2020-09-24 | 2021-09-22 | T細胞二重特異性抗体に関連する有害作用の予防又は緩和 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220088195A1 (https=) |
| EP (1) | EP4216998A1 (https=) |
| JP (1) | JP2023542212A (https=) |
| KR (1) | KR20230074146A (https=) |
| CN (1) | CN116322691A (https=) |
| AU (1) | AU2021350075A1 (https=) |
| BR (1) | BR112023005399A2 (https=) |
| CA (1) | CA3193478A1 (https=) |
| IL (1) | IL300543A (https=) |
| MX (1) | MX2023003133A (https=) |
| TW (1) | TW202228773A (https=) |
| WO (1) | WO2022063803A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| JP2025539760A (ja) * | 2022-11-15 | 2025-12-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合分子 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| MX375359B (es) | 2013-02-26 | 2025-03-06 | Roche Glycart Ag | Moléculas biespecíficas de unión a antígeno activadoras de células t. |
| JP6553069B2 (ja) * | 2013-11-07 | 2019-07-31 | メモリアル スローン ケタリング キャンサー センター | 抗wt1/hla二重特異性抗体 |
| JP6464255B2 (ja) | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性t細胞活性化抗原結合分子 |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2018183888A2 (en) * | 2017-03-31 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling |
| CN111699001A (zh) * | 2017-12-07 | 2020-09-22 | 尤利乌斯·马克西米利安维尔茨堡大学 | 达沙替尼和其他酪氨酸激酶抑制剂对基因修饰的嵌合抗原受体t细胞的功能的控制和调节 |
| SG11202005632SA (en) * | 2017-12-21 | 2020-07-29 | Hoffmann La Roche | Antibodies binding to hla-a2/wt1 |
| EP3863644A4 (en) * | 2018-10-12 | 2022-10-05 | Jeanmarie Guenot | CD33×CD3-BINDING PROTEINS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES |
-
2021
- 2021-09-22 CN CN202180065376.9A patent/CN116322691A/zh active Pending
- 2021-09-22 IL IL300543A patent/IL300543A/en unknown
- 2021-09-22 CA CA3193478A patent/CA3193478A1/en active Pending
- 2021-09-22 WO PCT/EP2021/075995 patent/WO2022063803A1/en not_active Ceased
- 2021-09-22 AU AU2021350075A patent/AU2021350075A1/en active Pending
- 2021-09-22 MX MX2023003133A patent/MX2023003133A/es unknown
- 2021-09-22 EP EP21782915.9A patent/EP4216998A1/en active Pending
- 2021-09-22 JP JP2023518392A patent/JP2023542212A/ja active Pending
- 2021-09-22 KR KR1020237009954A patent/KR20230074146A/ko active Pending
- 2021-09-22 BR BR112023005399A patent/BR112023005399A2/pt unknown
- 2021-09-23 TW TW110135298A patent/TW202228773A/zh unknown
- 2021-09-24 US US17/448,729 patent/US20220088195A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022050618A5 (https=) | ||
| JP2024156736A5 (https=) | ||
| Armuzzi et al. | Infliximab in the treatment of steroid-dependent ulcerative colitis | |
| JP2021528423A5 (https=) | ||
| JP2019515008A5 (https=) | ||
| FI3394103T3 (fi) | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon | |
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2008540447A5 (https=) | ||
| RU2015144666A (ru) | Терапия для лечения рака, включающая антитела против клаудина 18.2 | |
| JP2009518441A5 (https=) | ||
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| Österborg et al. | Strategies in the management of alemtuzumab-related side effects | |
| JP2021512107A5 (https=) | ||
| JP2024507283A (ja) | 抗腫瘍薬を調製するための免疫療法薬と併用でのppar-デルタ阻害剤の使用 | |
| JP2015172060A5 (https=) | ||
| Danese et al. | Biological Therapies for Inflammatory Bowel Disease: Research DrivesClinics | |
| JPWO2017172771A5 (https=) | ||
| JPWO2022063803A5 (https=) | ||
| CN111166878A (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| Martin | Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis | |
| JP2020521798A5 (https=) | ||
| Badn et al. | Inhibition of Inducible Nitric Oxide Synthase Enhances Anti‐tumour Immune Responses in Rats Immunized with IFN‐γ‐Secreting Glioma Cells | |
| CN117693350A (zh) | 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合 | |
| KR102944563B1 (ko) | 종양 치료용 약물의 제조에서 파미티닙과 조합된 항-pd-1 항체의 용도 |